Paul Toren

837 total citations
22 papers, 661 citations indexed

About

Paul Toren is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Paul Toren has authored 22 papers receiving a total of 661 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 8 papers in Pharmacology and 5 papers in Oncology. Recurrent topics in Paul Toren's work include Pharmacogenetics and Drug Metabolism (8 papers), Mass Spectrometry Techniques and Applications (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Paul Toren is often cited by papers focused on Pharmacogenetics and Drug Metabolism (8 papers), Mass Spectrometry Techniques and Applications (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). Paul Toren collaborates with scholars based in United States, Switzerland and United Kingdom. Paul Toren's co-authors include Andrew Parkinson, Brian W. Ogilvie, Donglu Zhang, A. David Rodrigues, Wenying Li, Faraz Kazmi, Brandy L. Paris, Phyllis Yerino, David B. Buckley and Ned R. Siegel and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Analytical Chemistry.

In The Last Decade

Paul Toren

19 papers receiving 603 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Paul Toren United States 11 284 206 193 96 86 22 661
Xavier Boulenc France 15 336 1.2× 198 1.0× 303 1.6× 78 0.8× 94 1.1× 19 814
Timothy J. Strelevitz United States 9 402 1.4× 237 1.2× 248 1.3× 88 0.9× 85 1.0× 13 722
Jairam Palamanda United States 19 339 1.2× 252 1.2× 223 1.2× 75 0.8× 92 1.1× 35 968
Hilde Bohets Belgium 11 311 1.1× 209 1.0× 254 1.3× 68 0.7× 72 0.8× 18 769
Lisa J. Christopher United States 15 181 0.6× 234 1.1× 339 1.8× 65 0.7× 90 1.0× 41 897
Ramaswamy A. Iyer United States 17 190 0.7× 277 1.3× 320 1.7× 54 0.6× 71 0.8× 49 992
Hiroshi Komura Japan 17 286 1.0× 245 1.2× 273 1.4× 82 0.9× 68 0.8× 40 817
Tsutomu Yoshimura Japan 13 171 0.6× 205 1.0× 183 0.9× 73 0.8× 88 1.0× 28 594
Susan Wong United States 17 314 1.1× 220 1.1× 248 1.3× 57 0.6× 98 1.1× 39 833
Kenneth J. Ruterbories United States 14 438 1.5× 211 1.0× 290 1.5× 173 1.8× 133 1.5× 37 990

Countries citing papers authored by Paul Toren

Since Specialization
Citations

This map shows the geographic impact of Paul Toren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Toren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Toren more than expected).

Fields of papers citing papers by Paul Toren

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Toren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Toren. The network helps show where Paul Toren may publish in the future.

Co-authorship network of co-authors of Paul Toren

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Toren. A scholar is included among the top collaborators of Paul Toren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Toren. Paul Toren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vaughn, Samuel, et al.. (2025). Cytochrome P450 2D6 *17 and *29 Allele Activity for Risperidone Metabolism: Advancing Precision Medicine Health Equity. Clinical Pharmacology & Therapeutics. 118(5). 1152–1160. 1 indexed citations
2.
Gaedigk, Andrea, Susan M. Abdel‐Rahman, Vincent S. Staggs, et al.. (2024). Influence of novel CYP2C‐haplotype on proton pump inhibitor pharmacokinetics in children. Clinical and Translational Science. 17(4). e13782–e13782. 2 indexed citations
3.
4.
Nolte, Whitney M., et al.. (2022). Simultaneous quantification of trimethoprim metabolites in pediatric plasma. Journal of Chromatography B. 1198. 123232–123232.
5.
Weir, Scott J., Elizabeth R. Kessler, Janet Baack Kukreja, et al.. (2022). Fosciclopirox clinical proof of concept in patients with nonmuscle invasive and muscle-invasive bladder cancer.. Journal of Clinical Oncology. 40(16_suppl). e16557–e16557.
6.
Chapron, Brian D., Jean Dinh, Paul Toren, Andrea Gaedigk, & J. Steven Leeder. (2020). The Respective Roles of CYP3A4 and CYP2D6 in the Metabolism of Pimozide to Established and Novel Metabolites. Drug Metabolism and Disposition. 48(11). 1113–1120. 5 indexed citations
7.
Weir, Scott J., Amanda E. Brinker, Paul Toren, et al.. (2019). Pharmacokinetics of ciclopirox prodrug, a novel agent for the treatment of bladder cancer, in animals and humans.. Journal of Clinical Oncology. 37(15_suppl). e14705–e14705. 6 indexed citations
8.
Altman, Ryan A., et al.. (2018). Tyr 1 -ψ[( Z )CF═CH]-Gly 2 Fluorinated Peptidomimetic Improves Distribution and Metabolism Properties of Leu-Enkephalin. ACS Chemical Neuroscience. 9(7). 1735–1742. 38 indexed citations
9.
Kazmi, Faraz, et al.. (2012). High-Resolution Mass Spectrometry Elucidates Metabonate (False Metabolite) Formation from Alkylamine Drugs during In Vitro Metabolite Profiling. Drug Metabolism and Disposition. 40(10). 1966–1975. 9 indexed citations
10.
Parkinson, Andrew, Faraz Kazmi, David B. Buckley, et al.. (2011). An Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes. Drug Metabolism and Disposition. 39(8). 1370–1387. 58 indexed citations
11.
Ogilvie, Brian W., Phyllis Yerino, Faraz Kazmi, et al.. (2011). The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel. Drug Metabolism and Disposition. 39(11). 2020–2033. 79 indexed citations
12.
Ogilvie, Brian W., Donglu Zhang, Wenying Li, et al.. (2005). GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS. Drug Metabolism and Disposition. 34(1). 191–197. 255 indexed citations
13.
14.
Violand, Bernard N., Michael R. Schlittler, Paul Toren, et al.. (1992). Isolation and characterization of porcine somatotropin containing a succinimide residue in place of aspartate129. Protein Science. 1(12). 1634–1641. 34 indexed citations
15.
Violand, Bernard N., B. D. Vineyard, Ned R. Siegel, et al.. (1991). Determination of the disulfide bond pairings in bovine transforming growth factor‐α. International journal of peptide & protein research. 37(6). 463–467. 16 indexed citations
16.
Violand, Bernard N., Michael R. Schlittler, Paul Toren, & Ned R. Siegel. (1990). Formation of isoaspartate 99 in bovine and porcine somatotropins. Journal of Protein Chemistry. 9(1). 109–117. 31 indexed citations
17.
Toren, Paul, et al.. (1988). Determination of interchain crosslinkages in insulin B-chain dimers by fast atom bombardment mass spectrometry. Analytical Biochemistry. 169(2). 287–299. 10 indexed citations
18.
Hortin, Glen L., Kam F. Fok, Paul Toren, & Arnold W. Strauss. (1987). Sulfation of a tyrosine residue in the plasmin-binding domain of alpha 2-antiplasmin.. Journal of Biological Chemistry. 262(7). 3082–3085. 47 indexed citations
19.
Cooks, R. Graham, et al.. (1986). Binding of first and subsequent glycerol molecules to organic and inorganic cations studied by desolvation in the mass spectrometer. Analytical Chemistry. 58(6). 1218–1221. 12 indexed citations
20.
Toren, Paul, et al.. (1986). Determination of impurities in nucleoside 3′-phosphoramidites by fast atom bombardment mass spectrometry. Analytical Biochemistry. 152(2). 291–294. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xavier Boulenc Breakdown of academic impact, for papers by Timothy J. Strelevitz Breakdown of academic impact, for papers by Jairam Palamanda Breakdown of academic impact, for papers by Hilde Bohets Breakdown of academic impact, for papers by Lisa J. Christopher Breakdown of academic impact, for papers by Ramaswamy A. Iyer Breakdown of academic impact, for papers by Hiroshi Komura Breakdown of academic impact, for papers by Tsutomu Yoshimura Breakdown of academic impact, for papers by Susan Wong Breakdown of academic impact, for papers by Kenneth J. Ruterbories
Rankless by CCL
2026